All In Biotech

Drug Trial Radar · NCT06641089

Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response

A Phase 3, Parallel-group, Randomized, Double-blind, 4-arm, Placebo-controlled, Multicenter Study With Risankizumab as Active Reference Arm, to Investigate the Efficacy and Safety of Subcutaneous Sonelokimab in Male and Female Participants Aged 18 Years and Over With Active Psoriatic Arthritis and Previous Inadequate Response or Intolerance to Tumor Necrosis Factor-α Inhibitors

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 600 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

600

Planned (sponsor's estimate)

Start

Oct 15, 2024

Primary completion

Jan 4, 2027

Study completion Sep 13, 2027

Sponsor

Lead sponsor
MoonLake Immunotherapeutics AGIndustry
Sponsor type
Industry
First posted
Oct 15, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a study to confirm the clinical efficacy and safety of sonelokimab compared with placebo in the treatment of adults with active psoriatic arthritis who have had a previous inadequate response or intolerance to anti-tumor necrosis factor (TNF)α therapy.

Conditions

  • Arthritis, Psoriatic

Interventions

  • SonelokimabDrug

    Sonelokimab

  • PlaceboDrug

    Placebo

  • RisankizumabDrug

    Active comparator

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Response rate of participants achieving at least a 50% improvement in the American College of Rheumatology criteria (ACR50)Time frame: Week 16 compared to placebo

Locations

143 sites in 11 countries. Site status is shown where the registry gives one.

  • Clinical Site

    Avondale, Arizona

  • Clinical Site

    Chandler, Arizona

  • Clinical Site

    Flagstaff, Arizona

  • Clinical Site

    Mesa, Arizona

  • Clinical Site

    Phoenix, Arizona

  • Clinical Site

    Scottsdale, Arizona

  • Clinical Site

    Tucson, Arizona

  • Clinical Site

    Jonesboro, Arkansas

  • Clinical Site

    La Jolla, California

  • Clinical Site

    Pomona, California

  • Clinical Site

    San Diego, California

  • Clinical Site

    Santa Monica, California

  • Clinical Site

    Thousand Oaks, California

  • Clinical Site

    Upland, California

  • Clinical Site

    Avon Park, Florida

  • Clinical Site

    Clearwater, Florida

  • Clinical Site

    Hialeah, Florida

  • Clinical Site

    Miami Gardens, Florida

  • Clinical Site

    Tampa, Florida

  • Clinical Site

    Zephyrhills, Florida

  • Clinical Site

    Gainesville, Georgia

  • Clinical Site

    Springfield, Illinois

  • Clinical Site

    Lake Charles, Louisiana

  • Clinical Site

    Baltimore, Maryland

  • Clinical Site

    Grand Blanc, Michigan

  • Clinical Site

    Brooklyn, New York

  • Clinical Site

    Rochester, New York

  • Clinical Site

    Charlotte, North Carolina

  • Clinical Site

    Leland, North Carolina

  • Clinical Site

    Middleburg Heights, Ohio

  • Clinical Site

    Portland, Oregon

  • Clinical Site

    Duncansville, Pennsylvania

  • Clinical Site

    Jackson, Tennessee

  • Clinical Site

    Memphis, Tennessee

  • Clinical Site

    Murfreesboro, Tennessee

  • Clinical Site

    Allen, Texas

  • Clinical Site

    Austin, Texas

  • Clinical Site

    Baytown, Texas

  • Clinical Site

    Colleyville, Texas

  • Clinical Site

    Houston, Texas

Showing 40 of 143 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.